The BNT162b2 coronavirus vaccine developed by Pfizer in collaboration with German based BioNTech, with the purpose of eradicating the global pandemic, has proven to be a huge success.
After the Pharma giant released its financial records for the first quarter ending March 30th, it was seen that Pfizer recorded 3.5 billion in sales from the vaccine alone.
“Based on what we have seen, we believe that a durable demand from our COVID-19 vaccine, similar to that of the flu vaccines, is a likely outcome”, said Pfizer CEO, Albert Bourla.
Estimates have shown that if this proves to be accurate, Pfizer will continue to profit from the sales of their COVID-19 vaccine.
Pfizer has quite a few competitors in the coronavirus vaccine market and even though newer and mutated variants of the virus have been emerging, which may cause to be an issue, the pharma giant expects to generate $26 billion in sales from the COVID-19 vaccine, this year itself.
The company definitely seem to have all basis covered. From the vaccine being very effective against all present variations of the virus, it is also prepared for future variations and mutations.
This showcases their level of confidence and are most definitely expecting a boost in its sales.
Excluding the COVID-19 vaccine the sales of the drug maker increased by 8%.
Hence, their growth looks promising and including their leading position in the coronavirus vaccine market, there are plenty of reasons to consider investing or purchasing shares of the company.